Essential Pharma announces acquisition of Ventavis from Bayer

Essential Pharma announces the acquisition of Ventavis from Bayer (BAYRY) AG, including rights to the accompanying Breelib nebuliser delivery technology. The company said, “The acquisition represents a significant milestone as Essential Pharma continues to grow its specialty rare disease franchise, reinforcing the Company’s mission to deliver medicines for small, underserved or rare disease populations globally. Ventavis, a prostacyclin analogue, is a well-established treatment for adult patients with primary pulmonary hypertension classified as NYHA functional class III, a rare condition where blood pressure is too high in the blood vessels between the heart and the lungs. Ventavis is used to improve exercise capacity and symptoms. It is administered through a nebuliser, such as Breelib, for targeted delivery of the drug to the lungs where it can work most effectively, resulting in improved blood flow, enhanced supply of oxygen to the body and reduced strain on the heart. The transaction expands Essential’s commercial presence in rare cardio-pulmonary disease, together with the acquisition of Colobreathe announced in early 2024, and develops the Company’s position in rare disease more generally.” Under the terms of the acquisition, Essential Pharma has acquired rights to Ventavis across all global markets, excluding the USA and Russia, and global rights to Breelib. The product is commercially available in over 60 markets globally.